Cracking the Undruggable Code: How Daraxonrasib Just Rewrote the Rules for Pancreatic Cancer Survival

A new drug targeting the mutation that drives 90% of pancreatic cancers has nearly doubled survival in a landmark Phase 3 trial, overturning four decades of scientific consensus that called this target impossible to treat.

Presented By Our Partners

Pancreatic cancer arrives quietly and leaves quickly. It is diagnosed at a late stage in roughly 80% of cases, produces almost no early symptoms, and carries a five-year survival rate of just 12 to 13 percent for all stages combined. For patients with metastatic disease, meaning cancer that has already spread at the time of diagnosis, median survival with standard chemotherapy has historically hovered around six to seven months. Those numbers have not moved meaningfully in decades. Until now.

On May 6, 2026, the New England Journal of Medicine published Phase 1/2 clinical trial data for daraxonrasib, a first-of-its-kind oral drug targeting the KRAS protein that drives tumor growth in over 90% of pancreatic cancer cases. The paper arrived alongside the announcement that a larger Phase 3 trial, called RASolute 302, had demonstrated a median overall survival of 13.2 months with daraxonrasib compared to 6.7 months on standard chemotherapy, with a hazard ratio of 0.40 and a p-value below 0.0001. In the language of oncology, that is not a modest improvement. That is a seismic one.

Forty Years of Failure: Why KRAS Was Called Undruggable

The story of KRAS begins in 1982, when researchers first identified activated RAS oncogenes in human cancer cell lines. The KRAS gene, one of three RAS family members, quickly emerged as the most frequently mutated oncogene in human cancer. It is present in altered form in roughly 25% of all solid tumors and in over 90% of pancreatic tumors, most commonly carrying the G12D mutation. Scientists recognized almost immediately that if you could block the mutated KRAS protein, you might be able to stop tumor growth in its tracks.

The problem was that no one could figure out how to do it. The KRAS protein, in its mutated state, binds very tightly to a molecule called guanosine triphosphate (GTP), and it has an extraordinarily smooth surface with very few pockets where a small drug molecule could attach. Early efforts in the 1980s and 1990s using so-called farnesyltransferase inhibitors, which tried to block KRAS from reaching the cell membrane where it activates cancer-driving signals, produced disappointing results in clinical trials. One by one, approaches collapsed. By the early 2000s, a scientific consensus had calcified: KRAS was undruggable, and the field moved on to target downstream proteins instead.

That consensus held for nearly 40 years. Then, in 2019, researchers at Mirati Therapeutics and Amgen published crystallographic studies showing that a previously unknown binding pocket appeared briefly in the KRAS G12C mutation variant. This discovery opened the door to covalent inhibitors that could lock into the mutated protein specifically. Sotorasib, targeting KRAS G12C, became the first approved therapy of this class in 2021, initially for lung cancer. But G12C is relatively rare in pancreatic cancer. The dominant mutations in the pancreas, particularly G12D and G12V, remained unaddressed. A truly pan-RAS approach was still needed.

The Science Behind Daraxonrasib: A New Class Entirely

Daraxonrasib, developed by Revolution Medicines, operates differently from the first-generation KRAS inhibitors. Rather than targeting a single mutation via a covalent bond, it belongs to a class called RAS(ON) multi-selective non-covalent inhibitors. The “ON” designation refers to the active, GTP-bound state of the RAS protein, which is the state that drives cancer signaling. The drug targets this active conformation across multiple RAS mutations simultaneously, making it far more broadly applicable than any prior approach.

In the pancreatic cancer context, this matters enormously. Pancreatic tumors harbor a mix of KRAS variants: G12D, G12V, G12R, and others. A drug that works across this spectrum can potentially treat the full population of KRAS-driven pancreatic cancer, not just the subset with one specific mutation. Daraxonrasib was designed precisely for this breadth, and the RASolute 302 Phase 3 trial enrolled patients with pancreatic tumors harboring a wide range of RAS variants, including some without an identified RAS mutation at all.

The drug is also taken orally, once daily. That is not a trivial distinction. Standard second-line chemotherapy for metastatic pancreatic cancer involves intravenous infusions, often on a weekly or biweekly schedule, with significant toxicity. An oral targeted therapy that can be taken at home represents a different relationship between patient and treatment, one that many patients with advanced cancer consider deeply meaningful.

The NEJM Phase 1/2 Data: A Safety and Signal Story

The Phase 1/2 trial published in the New England Journal of Medicine on May 6, 2026 (doi: 10.1056/NEJMoa2505783) represents the first detailed peer-reviewed report of daraxonrasib’s clinical activity in human patients with previously treated RAS-mutated metastatic pancreatic cancer. This was a first-in-human study, meaning it was primarily designed to establish a safe and tolerable dose while also capturing early signals of efficacy.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The headline finding at the 300 mg once-daily dose: approximately 30% of patients with one prior line of treatment experienced an objective response, meaning their tumors shrank by a measurable and clinically significant amount. Across all patients regardless of prior treatment lines, approximately 90% experienced disease control, a category that includes both objective responses and stable disease. The median duration of response exceeded 8.5 months for patients who had received one prior line of therapy.

Treatment-related adverse events were common: 96% of patients experienced at least one, and 30% experienced grade 3 or higher events. These numbers are high in absolute terms, but they need to be read in context. This is an advanced cancer population with very limited options, and the adverse event profile of daraxonrasib, while real, appears manageable and does not carry the peripheral neuropathy, severe nausea, and marrow suppression associated with cytotoxic chemotherapy. The safety data were described by investigators as consistent with a manageable profile, and they supported moving into a pivotal Phase 3 trial.

Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center were among the major research centers involved in the study, and the NEJM publication simultaneously accompanied an editorial titled “Advances in RAS Therapeutics for Pancreatic Cancer” (doi: 10.1056/NEJMe2600517), placing the trial in the context of a rapidly evolving therapeutic landscape.

The Phase 3 RASolute 302 Trial: Where the Numbers Become Historic

While the Phase 1/2 NEJM paper established proof of concept, the Phase 3 RASolute 302 results are where the full weight of this advance becomes clear. Revolution Medicines announced topline data in April 2026, and the results have since been described across the oncology community in terms rarely applied to pancreatic cancer outcomes.

Daraxonrasib demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared with standard of care cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The primary analysis in patients with RAS G12 mutations showed a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. The hazard ratio was 0.40, with a p-value below 0.0001. This means patients receiving daraxonrasib had a 60% lower risk of dying at any given point during follow-up compared with patients receiving chemotherapy.

To appreciate why 13.2 months matters, it helps to know where second-line pancreatic cancer therapy has historically sat. After failure of first-line treatment, median survival for most patients receiving standard chemotherapy regimens, including nanoliposomal irinotecan-based combinations, has ranged from roughly 4 to 7 months. Getting to 13.2 months in this population, with a tolerable oral pill, is a result that researchers at the Pancreatic Cancer Action Network called unprecedented in their public statement following the data release.

The FDA responded to the combined Phase 1/2 and Phase 3 data by issuing a “safe to proceed” letter permitting expanded access, allowing patients outside of clinical trials to receive daraxonrasib while full regulatory review proceeds. This is an unusual step that the agency reserves for cases where the benefit-risk profile is considered particularly compelling for a serious unmet need.

Context: What This Means for the Broader KRAS Landscape

Daraxonrasib does not exist in isolation. It sits at the leading edge of a broader revolution in RAS-targeted oncology that has been building since the first sotorasib approval in 2021. As of 2026, more than 17 additional KRAS G12C inhibitors, at least 5 G12D-specific inhibitors, and multiple pan-RAS approaches are in various stages of clinical evaluation. Daraxonrasib’s multi-selective, non-covalent mechanism positions it differently from the early covalent inhibitors, and its Phase 3 success in pancreatic cancer is likely to accelerate investment across the entire class.

It also raises important questions about combination strategies. Many researchers believe that RAS inhibitors may be most effective when paired with other agents, whether immunotherapy, MEK inhibitors, or other targeted drugs, to prevent the adaptive resistance that cancer cells reliably develop over time. The median response duration in the Phase 1/2 trial was 8.5 months, which means that most patients eventually progressed, even among those who initially responded. Understanding resistance mechanisms and designing combination approaches to overcome them will be a central focus of the next phase of this research.

For the broader landscape of pancreatic cancer detection and prevention, the emergence of effective targeted therapy also strengthens the case for earlier genomic profiling of all pancreatic tumors. If a drug like daraxonrasib can dramatically improve outcomes in previously treated metastatic disease, the potential benefit of deploying it at earlier stages, where disease burden is lower and responses might be deeper or more durable, becomes an urgent scientific and clinical question.

The Longevity Lens: Where This Fits the Larger Picture

Pancreatic cancer sits squarely within what the research community identifies as one of the four primary chronic disease threats to longevity: cancer. Alongside cardiovascular disease, neurodegenerative disease, and metabolic dysfunction, cancer remains a major ceiling on healthspan, and among all cancers, pancreatic is among the most feared precisely because it has been so resistant to the advances that have transformed outcomes in breast, lung, colorectal, and other tumor types over the past three decades.

The daraxonrasib story represents something more than a single drug’s success. It represents the closing of a 40-year gap, the proof that one of cancer’s most entrenched biological fortresses is not, in fact, impenetrable. That lesson echoes across the entire frontier of targeted oncology. KRAS mutations are found in 25% of all solid tumors. The population of patients who might ultimately benefit from effective RAS-targeted strategies extends well beyond pancreatic cancer to lung, colorectal, endometrial, and other tumor types.

The convergence of structural biology, machine learning-assisted drug design, and the clinical infrastructure to run global randomized trials with genomically defined patient populations has made this breakthrough possible. It is exactly the kind of precision medicine advance that longevity researchers have predicted for a decade: not a cure for aging, but a systematic dismantling, one mechanistic target at a time, of the diseases that cut lives short.

What This Means For You

Daraxonrasib is not yet approved by the FDA or any regulatory agency, so it is not currently available as a standard treatment. However, the trajectory is clear: given the Phase 3 survival data and the FDA’s expanded access decision, regulatory review is underway and approval pathways are being established. If you or someone you love has been diagnosed with pancreatic cancer, specifically metastatic disease that has been previously treated, there are several concrete steps worth taking now.

First, ask your oncologist about molecular profiling of the tumor. Standard genomic testing will identify KRAS mutation status and specific variant. This information is essential for determining eligibility for daraxonrasib and for any future RAS-targeted therapies. Second, ask about expanded access programs, which allow patients to receive investigational drugs before formal approval when the benefit-risk profile supports it. Third, consider consulting with a major cancer center such as Dana-Farber, MD Anderson, or Memorial Sloan Kettering, where access to emerging therapies and clinical trials is often greatest.

For those without a current pancreatic cancer diagnosis, the most powerful preventive actions remain metabolic: maintaining a healthy weight, avoiding or quitting smoking (which is the strongest modifiable risk factor for pancreatic cancer), managing blood sugar and insulin resistance, and minimizing alcohol consumption. Individuals with a family history of pancreatic cancer or with certain genetic variants, including BRCA2 mutations, should discuss surveillance protocols with their physician. Early detection through endoscopic ultrasound or MRI remains the best strategy for catching pancreatic cancer before it reaches the metastatic stage where survival data, even with a drug as promising as daraxonrasib, remains challenging.

What has changed this week is not the biology of pancreatic cancer. The cancer is as lethal as it has always been. What has changed is the foundation of what is now possible. Forty years of failure against KRAS has given way to a 13.2-month median survival in patients who previously faced fewer than seven. In oncology, that is not incremental progress. That is a different story entirely.

Sources: NEJM (doi: 10.1056/NEJMoa2505783), Revolution Medicines Phase 3 RASolute 302 announcement, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Pancreatic Cancer Action Network, Lustgarten Foundation, Targeted Oncology, OncLive, CancerNetwork.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.